NCT03348852

Brief Summary

In the study the investigators aim to test whether transcranial direct current stimulation (tDCS)-induced pain reduction is in association with functional changes in the brain measured with functional magnetic resonance imaging (fMRI) in patients with chronic inflammatory bowel diseases (IBD). Hypothesis: Transcranial direct current stimulation can reduce the perception of pain in patients with chronic inflammatory bowel diseases, which is in association with changes in the brain measured via fMRI.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jan 2017

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 24, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 22, 2017

Completed
6 months until next milestone

First Posted

Study publicly available on registry

November 21, 2017

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

September 27, 2021

Status Verified

September 1, 2021

Enrollment Period

5.9 years

First QC Date

May 22, 2017

Last Update Submit

September 24, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Functional and/or structural changes in the brain measured with cerebral MRI

    Participants will be followed for 2 weeks

    2 week

  • Changes in pain measured with visual analogue scale

    Participants will be followed for 2 weeks

    2 weeks

  • Changes in perception of pain measured with an algometer (pain pressure threshold)

    Participants will be followed for 2 weeks

    2 weeks

Secondary Outcomes (6)

  • Changes in questionnaire "quality of life"

    2 weeks

  • Changes in functional symptoms

    2 weeks

  • Changes in activity indices

    2 weeks

  • Changes in pain catastophizing scale

    2 weeks

  • Changes in inflammation biomarker (blood - C-reactive protein)

    2 weeks

  • +1 more secondary outcomes

Study Arms (2)

Active tDCS

ACTIVE COMPARATOR

Active transcranial direct current stimulation

Device: Transcranial direct current stimulation

Sham tDCS

SHAM COMPARATOR

Sham transcranial direct current stimulation

Device: Transcranial direct current stimulation

Interventions

Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.

Also known as: tDCS
Active tDCSSham tDCS

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Inflammatory bowel disease
  • Chronic pain (more than 3 months)
  • Pain (VAS \> 3/10)

You may not qualify if:

  • Contraindication to transcranial direct current stimulation
  • Contraindications to functional magnetic resonance imaging (fMRI)
  • Pregnancy
  • Sever internal or psychiatric condition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Charité University Medicine

Berlin, 12200, Germany

RECRUITING

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

GastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Study Officials

  • Magdalena S Prüß-Volz, MD

    Charite University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Magdalena S Prüß-Volz, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. med. Magdalena Sarah Prüß (geb. Volz)

Study Record Dates

First Submitted

May 22, 2017

First Posted

November 21, 2017

Study Start

January 24, 2017

Primary Completion

December 30, 2022

Study Completion

December 30, 2022

Last Updated

September 27, 2021

Record last verified: 2021-09

Locations